R A Agustinelli1, S H Rodrigues1, H A Mariz2, M S Prado1, L E C Andrade1,3. 1. 1 Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil. 2. 2 Rheumatology Division, Universidade Federal de Pernambuco, Recife, Brazil. 3. 3 Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.
Abstract
OBJECTIVE: The objective of this study was to determine whether characteristics of positive results in the indirect immunofluorescence assay on HEp-2 cells for anti-cell antibodies (HEp-2 IFA) differ between patients with non-autoimmune diseases (NADs) and patients with systemic autoimmune rheumatic diseases (SARDs). METHODS: Cross-sectional observational study comparing HEp-2 IFA test results in three groups: (a) 558 NAD patients comprising four subgroups (cancer ( n = 95), infectious diseases ( n = 148), psychiatric diseases ( n = 163), common non-infectious chronic diseases ( n = 152)); (b) 194 SARD patients; (c) 1217 healthy individuals (HIs). Sera were tested at 1:80 dilution and diluted to the end titer. Slides were analyzed by two independent blinded examiners. RESULTS: A positive HEp-2 IFA test occurred in 102 (18.3%) NAD patients, 170 (87.6%) SARD patients and 150 (12.3%) HIs. The four NAD subgroups did not differ regarding HEp-2 IFA frequency, titer or pattern. HEp-2 IFA titer was higher in NAD patients than in HIs and both had lower titer than SARD patients. Nuclear dense fine speckled pattern was more frequent in NAD patients and HIs than in SARD patients ( p < 0.001). Nuclear homogeneous and nuclear coarse speckled patterns were more frequent in SARD patients than in the other groups ( p < 0.001). The nuclear fine speckled pattern was prevalent in all three groups, but presented a gradient in titer across them; HIs and NAD patients had low and intermediary titers, which were significantly lower than in SARD patients ( p < 0.001). CONCLUSION: Positive HEp-2 IFA frequency, pattern and titer present differential features in NAD and SARD patients, and this attribute adds value to the test in the diagnosis of SARDs.
OBJECTIVE: The objective of this study was to determine whether characteristics of positive results in the indirect immunofluorescence assay on HEp-2 cells for anti-cell antibodies (HEp-2 IFA) differ between patients with non-autoimmune diseases (NADs) and patients with systemic autoimmune rheumatic diseases (SARDs). METHODS: Cross-sectional observational study comparing HEp-2 IFA test results in three groups: (a) 558 NADpatients comprising four subgroups (cancer ( n = 95), infectious diseases ( n = 148), psychiatric diseases ( n = 163), common non-infectious chronic diseases ( n = 152)); (b) 194 SARDpatients; (c) 1217 healthy individuals (HIs). Sera were tested at 1:80 dilution and diluted to the end titer. Slides were analyzed by two independent blinded examiners. RESULTS: A positive HEp-2 IFA test occurred in 102 (18.3%) NADpatients, 170 (87.6%) SARDpatients and 150 (12.3%) HIs. The four NAD subgroups did not differ regarding HEp-2 IFA frequency, titer or pattern. HEp-2 IFA titer was higher in NADpatients than in HIs and both had lower titer than SARDpatients. Nuclear dense fine speckled pattern was more frequent in NADpatients and HIs than in SARDpatients ( p < 0.001). Nuclear homogeneous and nuclear coarse speckled patterns were more frequent in SARDpatients than in the other groups ( p < 0.001). The nuclear fine speckled pattern was prevalent in all three groups, but presented a gradient in titer across them; HIs and NADpatients had low and intermediary titers, which were significantly lower than in SARDpatients ( p < 0.001). CONCLUSION: Positive HEp-2 IFA frequency, pattern and titer present differential features in NAD and SARDpatients, and this attribute adds value to the test in the diagnosis of SARDs.
Authors: Carlos Alberto von Mühlen; Ignacio Garcia-De La Torre; Maria Infantino; Jan Damoiseaux; Luis E C Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Minoru Satoh; Lucile Musset; Edward K L Chan Journal: Immunol Res Date: 2021-10-09 Impact factor: 2.829
Authors: Wilton Ferreira Silva Santos; Ana Paula de Castro Cantuária; Daniele de Castro Félix; Leandro Kegler Nardes; Igor Cabral Santos de Melo Journal: Adv Rheumatol Date: 2022-08-15
Authors: Nadja Röber; Alessandra Dellavance; Fernanda Ingénito; Marie-Luise Reimer; Orlando Gabriel Carballo; Karsten Conrad; Edward K L Chan; Luis E C Andrade Journal: Front Immunol Date: 2021-10-05 Impact factor: 7.561